hC Bioscience Announces Lead Program in Hemophilia and Reports Positive Preclinical Data on Novel Protein Editing Approach Using Anticodon Engineered tRNA

BOSTON--(BUSINESS WIRE)--hC Bioscience announces lead program in severe hemophilia A and shares preclinical data demonstrating proof-of-concept for tRNA-based protein editing.